WELICHEM SUCCESSFULLY COMPLETES TWO PHASE II CLINICAL TRIALS OF WBI-1001 CREAM IN PATIENTS WITH PSORIASIS AND ATOPIC DERMATITIS

VANCOUVER, Feb. 2 /CNW/ -- 
VANCOUVER, Feb. 2 /CNW/ - Welichem Biotech is pleased to announce the
 successful completion of two Phase II clinical trials with WBI-1001 on
 psoriasis and atopic dermatitis. Both studies were 12-week,
 double-blinded, placebo-controlled clinical trials conducted under the
 regulatory guidelines of Health Canada. Based on analysis of the data,
 both the primary and secondary efficacy and safety endpoints were met
 in both studies.


ON BEHALF OF THE BOARD


Dr. John M. Webster, Chairman of the Board


About Welichem Biotech Inc.


Welichem Biotech Inc. is a publicly-traded biotechnology company
 developing therapeutic drugs in the fields of autoimmune disease and
 cancer.


To view this news release in HTML formatting, please use the following URL: http://www.newswire.ca/en/releases/archive/February2011/02/c7375.html



pLiren Tang, PhD.br/ Chief Executive Officer.br/ Tel.: [phone], E-mail: a href="mailto:[e-mail]"[e-mail]/a/p

Copyright